Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1953 2
1954 1
1955 1
1956 2
1957 1
1958 1
1961 3
1962 2
1963 1
1966 1
1967 3
1969 3
1970 6
1971 2
1972 1
1974 1
1976 1
1977 1
1978 4
1979 1
1980 7
1981 3
1982 2
1983 5
1984 6
1985 8
1986 6
1987 9
1988 3
1989 4
1990 12
1991 10
1992 5
1993 13
1994 11
1995 11
1996 12
1997 15
1998 8
1999 21
2000 16
2001 19
2002 21
2003 21
2004 20
2005 28
2006 24
2007 30
2008 23
2009 26
2010 33
2011 28
2012 41
2013 33
2014 23
2015 24
2016 36
2017 44
2018 46
2019 45
2020 59
2021 65
2022 73
2023 68
2024 66

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

999 results

Results by year

Filters applied: . Clear all
Page 1
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Kopyltsov E, Méndez-Vidal MJ, Kozlov V, Alyasova A, Hong SH, Kapoor A, Alonso Gordoa T, Merchan JR, Winquist E, Maroto P, Goh JC, Kim M, Gurney H, Patel V, Peer A, Procopio G, Takagi T, Melichar B, Rolland F, De Giorgi U, Wong S, Bedke J, Schmidinger M, Dutcus CE, Smith AD, Dutta L, Mody K, Perini RF, Xing D, Choueiri TK; CLEAR Trial Investigators. Motzer R, et al. Among authors: eto m. N Engl J Med. 2021 Apr 8;384(14):1289-1300. doi: 10.1056/NEJMoa2035716. Epub 2021 Feb 13. N Engl J Med. 2021. PMID: 33616314 Clinical Trial.
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.
Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Alekseev B, Rha SY, Merchan J, Goh JC, Lalani AA, De Giorgi U, Melichar B, Hong SH, Gurney H, Méndez-Vidal MJ, Kopyltsov E, Tjulandin S, Gordoa TA, Kozlov V, Alyasova A, Winquist E, Maroto P, Kim M, Peer A, Procopio G, Takagi T, Wong S, Bedke J, Schmidinger M, Rodriguez-Lopez K, Burgents J, He C, Okpara CE, McKenzie J, Choueiri TK; CLEAR Trial Investigators. Motzer RJ, et al. Among authors: eto m. J Clin Oncol. 2024 Apr 10;42(11):1222-1228. doi: 10.1200/JCO.23.01569. Epub 2024 Jan 16. J Clin Oncol. 2024. PMID: 38227898 Free PMC article. Clinical Trial.
Reply by Authors.
Kobayashi S, Cho B, Mutaguchi J, Inokuchi J, Tatsugami K, Hashizume M, Eto M. Kobayashi S, et al. Among authors: eto m. J Urol. 2020 Jul;204(1):156. doi: 10.1097/JU.0000000000000709.02. Epub 2020 Apr 23. J Urol. 2020. PMID: 32324094 No abstract available.
Comparison of therapeutic features and oncologic outcome in patients with pN1 prostate cancer among robot-assisted, laparoscopic, or open radical prostatectomy.
Kirisawa T, Shiota M, Kimura T, Edamura K, Miyake M, Morizane S, Yoshino T, Matsukawa A, Matsumoto R, Kasahara T, Nishiyama N, Eto M, Kitamura H, Nakamura E, Matsui Y; Japanese Urological Oncology Group. Kirisawa T, et al. Among authors: eto m. Int J Clin Oncol. 2023 Feb;28(2):306-313. doi: 10.1007/s10147-022-02278-7. Epub 2022 Dec 17. Int J Clin Oncol. 2023. PMID: 36527579
Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms.
Grünwald V, Powles T, Eto M, Kopyltsov E, Rha SY, Porta C, Motzer R, Hutson TE, Méndez-Vidal MJ, Hong SH, Winquist E, Goh JC, Maroto P, Buchler T, Takagi T, Burgents JE, Perini R, He C, Okpara CE, McKenzie J, Choueiri TK. Grünwald V, et al. Among authors: eto m. Front Oncol. 2023 Aug 16;13:1223282. doi: 10.3389/fonc.2023.1223282. eCollection 2023. Front Oncol. 2023. PMID: 37664025 Free PMC article.
Cancer du rein cliniquement localisé : quels sont les facteurs prédictifs du risque d'upstaging pathologique pT3a par invasion de la graisse ?
Bernhard J, Patard J, Bigot P, Suer E, Vuong N, Verhoest G, Alimi Q, Flamand V, Reix B, Beauval J, Benoit T, Nouhaud F, Lenormand C, Hamidi N, Eto M, Larre S, El Bakri A, Baco E, Ploussard G, Koutlidis N, Schneider A, Roupret M, Leon P, Carrouget J, Droupy S, Marchal S. Bernhard J, et al. Among authors: eto m. Prog Urol. 2015 Nov;25(13):800. doi: 10.1016/j.purol.2015.08.169. Prog Urol. 2015. PMID: 26544364 French. No abstract available.
Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study.
Motzer RJ, Choueiri TK, Hutson T, Young Rha S, Puente J, Lalani AA, Winquist E, Eto M, Basappa NS, Tannir NM, Vaishampayan U, Bjarnason GA, Oudard S, Grünwald V, Burgents J, Xie R, McKenzie J, Powles T. Motzer RJ, et al. Among authors: eto m. Eur Urol. 2024 Jul;86(1):4-9. doi: 10.1016/j.eururo.2024.03.015. Epub 2024 Apr 6. Eur Urol. 2024. PMID: 38582713 Free article. Clinical Trial.
999 results